Lisata Therapeutics, Inc. (LON: 0HS8)

London flag London · Delayed Price · Currency is GBP · Price in USD
3.950
+0.222 (5.96%)
At close: Jan 21, 2025
33.36%
Market Cap 18.74M
Revenue (ttm) n/a
Net Income (ttm) -15.47M
Shares Out n/a
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 500
Average Volume 1,324
Open 3.950
Previous Close 3.728
Day's Range 3.950 - 3.950
52-Week Range 2.061 - 2.990
Beta 1.22
RSI 65.53
Earnings Date Mar 26, 2025

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ c... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1980
Employees 25
Stock Exchange London Stock Exchange
Ticker Symbol 0HS8
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.